Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Harvard Bioscience (HBIO) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Harvard Bioscience (HBIO) over the last 17 years, with Q3 2025 value amounting to 0.18.

  • Harvard Bioscience's Equity Ratio fell 6376.02% to 0.18 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.18, marking a year-over-year decrease of 6376.02%. This contributed to the annual value of 0.5 for FY2024, which is 598.23% down from last year.
  • As of Q3 2025, Harvard Bioscience's Equity Ratio stood at 0.18, which was down 6376.02% from 0.2 recorded in Q2 2025.
  • Over the past 5 years, Harvard Bioscience's Equity Ratio peaked at 0.53 during Q4 2023, and registered a low of 0.18 during Q3 2025.
  • Its 5-year average for Equity Ratio is 0.46, with a median of 0.5 in 2024.
  • Its Equity Ratio has fluctuated over the past 5 years, first surged by 858.05% in 2023, then crashed by 6402.57% in 2025.
  • Harvard Bioscience's Equity Ratio (Quarter) stood at 0.51 in 2021, then decreased by 3.29% to 0.5 in 2022, then grew by 7.07% to 0.53 in 2023, then dropped by 5.98% to 0.5 in 2024, then plummeted by 63.93% to 0.18 in 2025.
  • Its Equity Ratio was 0.18 in Q3 2025, compared to 0.2 in Q2 2025 and 0.19 in Q1 2025.